Abeona Therapeutics Past Earnings Performance
Past criteria checks 0/6
Abeona Therapeutics has been growing earnings at an average annual rate of 8.8%, while the Biotechs industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 6.5% per year.
Key information
8.8%
Earnings growth rate
38.0%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 6.5% |
| Return on equity | -365.5% |
| Net Margin | -1,548.2% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Abeona Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 4 | -54 | 19 | 30 |
| 30 Sep 23 | 4 | -45 | 19 | 1 |
| 30 Jun 23 | 4 | -39 | 19 | 0 |
| 31 Mar 23 | 1 | -31 | 17 | 0 |
| 31 Dec 22 | 1 | -43 | 17 | 28 |
| 30 Sep 22 | 4 | -83 | 16 | 22 |
| 30 Jun 22 | 4 | -84 | 18 | 0 |
| 31 Mar 22 | 3 | -91 | 20 | 0 |
| 31 Dec 21 | 3 | -85 | 22 | 0 |
| 30 Sep 21 | 3 | -54 | 25 | 0 |
| 30 Jun 21 | 10 | -54 | 23 | 0 |
| 31 Mar 21 | 10 | -52 | 24 | 0 |
| 31 Dec 20 | 10 | -84 | 24 | 0 |
| 30 Sep 20 | 7 | -85 | 21 | 0 |
| 30 Jun 20 | 0 | -95 | 21 | 0 |
| 31 Mar 20 | 0 | -106 | 21 | 0 |
| 31 Dec 19 | 0 | -76 | 21 | 0 |
| 30 Sep 19 | 0 | -77 | 24 | 0 |
| 30 Jun 19 | 2 | -76 | 24 | 0 |
| 31 Mar 19 | 2 | -65 | 23 | 0 |
| 31 Dec 18 | 3 | -57 | 20 | 0 |
| 30 Sep 18 | 3 | -48 | 16 | 0 |
| 30 Jun 18 | 1 | -37 | 13 | 0 |
| 31 Mar 18 | 1 | -33 | 11 | 0 |
| 31 Dec 17 | 1 | -27 | 11 | 0 |
| 30 Sep 17 | 1 | -26 | 11 | 3 |
| 30 Jun 17 | 1 | -23 | 11 | 6 |
| 31 Mar 17 | 1 | -22 | 12 | 9 |
| 31 Dec 16 | 1 | -22 | 13 | 0 |
| 30 Sep 16 | 1 | -17 | 15 | 10 |
| 30 Jun 16 | 1 | -21 | 17 | 9 |
| 31 Mar 16 | 1 | -18 | 17 | 6 |
| 31 Dec 15 | 1 | -15 | 14 | 5 |
| 30 Sep 15 | 1 | -25 | 11 | 3 |
| 30 Jun 15 | 1 | -21 | 7 | 1 |
| 31 Mar 15 | 1 | -30 | 4 | 1 |
| 31 Dec 14 | 1 | -30 | 4 | 0 |
| 30 Sep 14 | 1 | -19 | 4 | 0 |
| 30 Jun 14 | 1 | -17 | 4 | 1 |
| 31 Mar 14 | 1 | -3 | 5 | 1 |
| 31 Dec 13 | 2 | 2 | 5 | 1 |
| 30 Sep 13 | 3 | 22 | 6 | 1 |
| 30 Jun 13 | 4 | 8 | 6 | 1 |
Quality Earnings: PCJ is currently unprofitable.
Growing Profit Margin: PCJ is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PCJ is unprofitable, but has reduced losses over the past 5 years at a rate of 8.8% per year.
Accelerating Growth: Unable to compare PCJ's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PCJ is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-1.3%).
Return on Equity
High ROE: PCJ has a negative Return on Equity (-365.49%), as it is currently unprofitable.